Alpha Cognition

ACOG · NASDAQ

$8.61+$0.11 (+1.29%)TodayMarket closed · Oct 20, 4:10 PM ET

Prev close $8.50

About ACOG

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.

Employees: 71
Headquarters: Vancouver, British Columbia
Listed: Jun 9, 2021
Sector: Health Care
Industry: Biotechnology
Website: alphacognition.com

Leadership

Alpha Cognition executives
Name	Title	Since	Age
Len Mertz	—	—	69
Michael Mcfadden	—	2021	57
Henry Du	—	—	46
Lauren D'Angelo	—	—	46
Kenneth Cawkell	—	2021	74
Rajeev Bakshi	—	—	65
Phillip Mertz	—	—	40
Robert Wills	—	—	71
Robert Lynch	—	2025	—

Similar companies

Companies in the same industry as Alpha Cognition

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.